Loading...

DYN DYNE THERAPEUTICS INC Expansion Plans 8-K Filing

DYN

DYN

DYNE THERAPEUTICS INC

(DYN)

2025 8-K

Show Summary

Show Summary

Accelerated Approval Pathway

Financial Statements

Management Change

Financial Results

Financial Update

Financial Results

Leadership Changes

Financial Results

Annual Meeting of Stockholders

Public Offering

Clinical Trial Results

Financial Results Announcement

Appointment of President an...

Financial Results Announcement

Public Offering

Suspension of Prospectus

Clinical Trial Results

Financial Results Announcement

Financial Results Announcement

Departure of Directors

Financial Results Announcement

Regulation FD Disclosure

Financial Results Announcement

External Links:

On June 17, 2025, Dyne Therapeutics announced that the FDA granted Breakthrough Therapy Designation to their drug DYNE-101 for treating myotonic dystrophy type 1 (DM1), alongside a revised plan for obtaining U.S. Accelerated Approval based on new lon

AI Assistant

DYNE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.